Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi reports positive cholesterol trial data for alirocumab

Sanofi reports positive cholesterol trial data for alirocumab

16th October 2013

Sanofi and Regeneron Pharmaceuticals have announced positive findings from Odyssey Mono, a phase III trial assessing the new compound alirocumab as a means of reducing cholesterol levels.

The investigational monoclonal antibody was shown to be three times more effective than an alternative therapy in reducing levels of low-density lipoprotein-cholesterol, more commonly known as bad cholesterol.

This study utilised an up-titration approach with the aim of bringing patients to goal with the lowest effective dose of anti-PCSK9 antibody therapy.

Odyssey Mono was the first study to report data from the 12 phase III trials that have been initiated so far as part of the Odyssey clinical trial programme, which has involved more than 23,000 patients.

Dr Jay Edelberg, head of the PCSK9 development and launch unit at Sanofi, said: "We look forward to results from the remaining phase III trials, which are investigating alirocumab in a variety of patient populations, combinations with different background therapies and dosing regimens."

This comes after Sanofi and Genzyme presented new clinical data reinforcing the positive safety and efficacy profile of the multiple sclerosis therapy Aubagio earlier this month.ADNFCR-8000103-ID-801649924-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.